Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that members of its management will be attending the upcoming SVB Leerink Biopharma Private Company Connect Event.
Mission Therapeutics takes part in SVB Leerink Biopharma Private Company Connect event
The event, which will take place virtually on 6-7 May 2021, is intended to bring together private companies with institutional investors and to facilitate discussions on the trends and opportunities shaping the future of healthcare. For individuals interested in attending the conference, please contact SVB Leerink for more information.
MISSION Therapeutics is a specialist pharmaceutical company whose aim is to translate new molecular understandings of human cell biology into drugs that will markedly improve the management of life-threatening diseases, particularly cancer.